Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Can J Cardiol. 2011 Nov-Dec;27(6):756-62. doi: 10.1016/j.cjca.2011.06.005. Epub 2011 Sep 14.
Quality indicators in coronary heart disease (CHD) measure the practice gap between optimal care and current clinical practice. However, the potential impact of achieving quality indicator benchmarks remains unknown.
Using a validated, epidemiologic model of CHD in Ontario, Canada, we estimated the potential impact on mortality of improved utilization on CHD quality indicators from 2005 levels to recommend benchmark utilization of 90%. Eight CHD disease subgroups were evaluated, including inpatients with acute myocardial infarction (AMI), acute coronary syndromes, and heart failure, in addition to ambulatory patients who were post-acute myocardial infarction survivors, or had heart failure, chronic stable angina, hypertension, or hyperlipidemia. The primary outcome was the predicted mortality reduction associated with meeting quality indicator targets for each CHD subgroup-treatment combination.
In 2005, there were 10,060 CHD deaths in Ontario, representing an age-adjusted CHD mortality of 191 per 100,000 people. By meeting quality indicator utilization benchmarks, mortality could be potentially reduced by approximately 20% (95% confidence interval 17.8-21.1), representing approximately 1960 avoidable deaths. The bulk of this potential benefit was in ambulatory patients with chronic stable angina (36% of reduction) and heart failure (31% of reduction). The biggest drivers were optimizing angiotensin-converting enzyme inhibitor use in chronic stable angina patients (approximately 440 avoidable deaths) and β-blocker use in heart failure (approximately 400 avoidable deaths).
These findings reinforce the importance of quality indicators and could aid policy makers in prioritizing strategies to meet the goals outlined in the Canadian Heart Health Strategy and Action Plan for reducing cardiovascular mortality.
冠心病(CHD)质量指标衡量了最佳治疗与当前临床实践之间的实践差距。然而,实现质量指标基准的潜在影响尚不清楚。
我们使用经过验证的加拿大安大略省 CHD 流行病学模型,估计了从 2005 年水平提高 CHD 质量指标的利用度,达到推荐的 90%基准利用度对死亡率的潜在影响。评估了八个 CHD 疾病亚组,包括急性心肌梗死(AMI)、急性冠状动脉综合征和心力衰竭的住院患者,以及急性心肌梗死后幸存者、心力衰竭、慢性稳定型心绞痛、高血压或高血脂的门诊患者。主要结果是与每个 CHD 亚组-治疗组合达到质量指标目标相关的预测死亡率降低。
2005 年,安大略省有 10060 例 CHD 死亡,年龄调整后的 CHD 死亡率为每 10 万人 191 人。通过达到质量指标的利用度基准,可以潜在降低约 20%(95%置信区间为 17.8-21.1)的死亡率,即大约可避免 1960 人死亡。这种潜在益处的大部分来自慢性稳定型心绞痛(降低 36%)和心力衰竭(降低 31%)的门诊患者。最大的驱动因素是优化慢性稳定型心绞痛患者的血管紧张素转换酶抑制剂的使用(约可避免 440 人死亡)和心力衰竭患者的β受体阻滞剂的使用(约可避免 400 人死亡)。
这些发现强调了质量指标的重要性,并可能有助于决策者确定策略,以实现加拿大心脏健康战略和行动计划中降低心血管死亡率的目标。